May 21, 2020 / 11:29 AM / 2 months ago

BRIEF-Sorrento Enters Into Binding Term Sheet To Acquire Exclusive Rights To Abivertinib With Completed Registrational Trial Data In Non-Small Cell Lung Cancer

May 21 (Reuters) - Sorrento Therapeutics Inc:

* SORRENTO ENTERS INTO BINDING TERM SHEET TO ACQUIRE EXCLUSIVE RIGHTS TO ABIVERTINIB WITH COMPLETED REGISTRATIONAL TRIAL DATA IN NON-SMALL CELL LUNG CANCER

* SORRENTO THERAPEUTICS INC - FINAL TERMS OF LICENSE WILL BE SET FORTH IN A DEFINITIVE AGREEMENT TO BE ENTERED INTO BETWEEN PARTIES

* SORRENTO THERAPEUTICS - PROMPTLY AFTER AGREEMENT, CO EXPECTS TO MEET WITH FDA TO DISCUSS DATA, PATH FORWARD TO SEEK APPROVAL FOR ONCOLOGIC INDICATIONS Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below